Reported Earnings • May 28
Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2026 results: EPS: UK£0.029 (up from UK£1.27 loss in FY 2025). Revenue: UK£666.1m (up 12% from FY 2025). Net income: UK£4.10m (up UK£182.8m from FY 2025). Profit margin: 0.6% (up from net loss in FY 2025). Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) missed analyst estimates by 90%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Insurance industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • May 27
Saga plc, Annual General Meeting, Jun 30, 2026 Saga plc, Annual General Meeting, Jun 30, 2026. Location: the office of herbert smith freehills kramer, exchange house, primrose street, ec2a 2eg, london United Kingdom Annuncio • May 26
Saga plc to Report First Half, 2027 Results on Sep 30, 2026 Saga plc announced that they will report first half, 2027 results on Sep 30, 2026 New Risk • Apr 17
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Large one-off items impacting financial results. Reported Earnings • Apr 16
Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2026 results: EPS: UK£0.028 (up from UK£1.27 loss in FY 2025). Revenue: UK£666.1m (up 12% from FY 2025). Net income: UK£4.10m (up UK£182.8m from FY 2025). Profit margin: 0.6% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) missed analyst estimates by 90%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Insurance industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Mar 23
Saga plc Announces Committee Changes In accordance with Listing Rule 6.4.6, the Board of Saga plc announced that Gemma Godfrey has been appointed Chair of the Remuneration Committee and the Non-Executive Director nominated as the Board's 'People Champion', with immediate effect. In line with the continued simplification of business model, the decision has been made to disband the Innovation and Enterprise Committee, with immediate effect. Previous members for this committee included Anand Aithal (Chair), Roger De Haan, Gemma Godfrey and Gareth Hoskin. There are no changes to the Audit and Risk, or Nomination, Committees. Annuncio • Feb 28
Julie Hopes Steps Down from Position of Non-Executive Director, Saga Plc, Effective from February 27, 2026 Saga plc announced that Julie Hopes, Non-Executive Director since October 1, 2018, is stepping down from the Board with effect from February 27, 2026, to focus on other opportunities. The Board will review the composition of its committees and will announce any changes in due course following Julie Hopes' departure. New Risk • Jan 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Annuncio • Jan 20
Saga plc to Report Fiscal Year 2026 Results on Apr 15, 2026 Saga plc announced that they will report fiscal year 2026 results on Apr 15, 2026 New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Sep 25
First half 2026 earnings released: EPS: UK£0.042 (vs UK£0.76 loss in 1H 2025) First half 2026 results: EPS: UK£0.042 (up from UK£0.76 loss in 1H 2025). Revenue: UK£330.9m (down 20% from 1H 2025). Net income: UK£5.90m (up UK£112.0m from 1H 2025). Profit margin: 1.8% (up from net loss in 1H 2025). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Insurance industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 39% per year. Annuncio • Jul 10
Saga plc Announces Committee Changes Saga plc announced that, in line with the continued simplification of our business model, the decision has been made to merge the Audit and Risk Committees, with immediate effect. The membership of the combined Audit and Risk Committee will be Gareth Hoskin (Chair), Anand Aithal and Julie Hopes. Gemma Godfrey has stepped down as a member of the Risk Committee. There are no changes to the Innovation and Enterprise, Nomination or Remuneration Committees. Annuncio • Jun 24
Saga plc to Report First Half, 2026 Results on Sep 24, 2025 Saga plc announced that they will report first half, 2026 results on Sep 24, 2025 Annuncio • May 20
Saga plc, Annual General Meeting, Jun 24, 2025 Saga plc, Annual General Meeting, Jun 24, 2025. Location: the office of numis securities limited, 45 gresham street, ec2v 7bf, london United Kingdom Recent Insider Transactions • Apr 13
Non-Executive Chairman recently bought UK£2.0m worth of stock On the 9th of April, Roger De Haan bought around 1m shares on-market at roughly UK£1.35 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Roger's only on-market trade for the last 12 months. Reported Earnings • Apr 11
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: UK£1.27 loss per share (further deteriorated from UK£0.81 loss in FY 2024). Revenue: UK£594.4m (down 21% from FY 2024). Net loss: UK£178.7m (loss widened 58% from FY 2024). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 38%. Revenue is forecast to grow 1.0% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Insurance industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Annuncio • Apr 09
Saga plc Announces Board and Committee Change, with Effect from 9 April 2025 The Board of Saga announces that Sir Peter Bazalgette, Senior Independent Director, and Steve Kingshott, Executive Director, are stepping down from the Board with effect from 9 April 2025. These changes to the Board follow Saga's successful Insurance agreement with wholly owned UK subsidiaries of Ageas SA/NV, and reflect the Group's newsimplified business model. Sir Peter, who chairs the Nomination Committee, is also a member of the Remuneration Committee. The Company announces that Gareth Hoskin will become Senior Independent Director, Chair of the Nomination Committee and a member of the Remuneration Committee. Julie Hopes will become a member of the Nomination Committee. These changes take effect from 9 April 2025. Following the changes above, the membership of the Nomination and Remuneration Committees will be as follows: Nomination Committee: Gareth Hoskin (Chair), Anand Aithal. Sir Roger De Haan, Gemma Godfrey and Julie Hopes. Remuneration Committee: Julie Hopes (Chair), Gemma Godfrey and Gareth Hoskin. There are no changes to the Audit, Innovation and Enterprise or Risk Committees. Price Target Changed • Apr 01
Price target increased by 11% to UK£1.53 Up from UK£1.37, the current price target is an average from 2 analysts. New target price is 20% above last closing price of UK£1.27. Stock is up 7.8% over the past year. The company posted a net loss per share of UK£0.81 last year. New Risk • Mar 31
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£148m Forecast net loss in 1 year: UK£42m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Annuncio • Feb 13
Saga plc Announces Executive Changes Saga plc announced that Steve Kingshott will be standing down from his role as the Chief Executive Officer (CEO) of Insurance, with effect from 12 February 2025, and will be assuming the role of specialist adviser, advising on the delivery and implementation of the 20-year partnership with Ageas for its motor and home Insurance Broking business. The CEO of Insurance role will be filled by Lloyd East, currently Chief Operating Officer of Insurance, subject to regulatory approval. Steve Kingshott will remain an executive director of the company. Annuncio • Jan 30
Saga plc to Report Fiscal Year 2025 Results on Apr 09, 2025 Saga plc announced that they will report fiscal year 2025 results on Apr 09, 2025 Price Target Changed • Jan 28
Price target decreased by 8.4% to UK£1.37 Down from UK£1.50, the current price target is an average from 2 analysts. New target price is 19% above last closing price of UK£1.15. Stock is down 19% over the past year. The company is forecast to post earnings per share of UK£0.19 next year compared to a net loss per share of UK£0.81 last year. Reported Earnings • Oct 13
First half 2025 earnings released: UK£0.76 loss per share (vs UK£0.51 loss in 1H 2024) First half 2025 results: UK£0.76 loss per share (further deteriorated from UK£0.51 loss in 1H 2024). Revenue: UK£412.3m (up 16% from 1H 2024). Net loss: UK£106.1m (loss widened 49% from 1H 2024). Revenue is expected to decline by 1.6% p.a. on average during the next 3 years, while revenues in the Insurance industry in the United Kingdom are expected to grow by 9.8%. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Annuncio • Oct 11
Saga plc to Report First Half, 2025 Results on Oct 11, 2024 Saga plc announced that they will report first half, 2025 results on Oct 11, 2024 Price Target Changed • May 09
Price target decreased by 9.4% to UK£1.48 Down from UK£1.63, the current price target is an average from 3 analysts. New target price is 31% above last closing price of UK£1.13. Stock is down 2.7% over the past year. The company is forecast to post earnings per share of UK£0.25 next year compared to a net loss per share of UK£0.81 last year. New Risk • Apr 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 21
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: UK£0.81 loss per share (improved from UK£1.86 loss in FY 2023). Revenue: UK£754.9m (up 29% from FY 2023). Net loss: UK£113.0m (loss narrowed 56% from FY 2023). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 133%. Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Insurance industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings. New Risk • Apr 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Price Target Changed • Mar 12
Price target decreased by 11% to UK£1.55 Down from UK£1.75, the current price target is an average from 3 analysts. New target price is 25% above last closing price of UK£1.24. Stock is down 19% over the past year. The company is forecast to post a net loss per share of UK£0.35 next year compared to a net loss per share of UK£1.86 last year. Major Estimate Revision • Feb 04
Consensus EPS estimates upgraded to UK£0.35 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -UK£0.386 to -UK£0.347 per share. Revenue forecast steady at UK£660.7m. Insurance industry in the United Kingdom expected to see average net income growth of 148% next year. Consensus price target down from UK£1.75 to UK£1.63. Share price fell 21% to UK£1.23 over the past week. Major Estimate Revision • Jan 30
Consensus revenue estimates decrease by 13%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from UK£662.3m to UK£578.0m. EPS estimate increased from UK£0.44 to UK£0.502 per share. Net income forecast to grow 82% next year vs 149% growth forecast for Insurance industry in the United Kingdom. Consensus price target up from UK£1.65 to UK£1.73. Share price fell 2.4% to UK£1.45 over the past week. Annuncio • Jan 30
Saga plc Provides Earnings Guidance for the Year 2023/2024 Saga plc provided earnings guidance for the year 2023/2024. For the year, the Group is expected to report revenue growth of between 10% to 15%. Annuncio • Dec 22
Saga plc Announces Directorate Change The Board of Saga announced that Eva Eisenschimmel, Non-Executive Director since 1 January 2019, is stepping down from the Board to allow her to completely focus on her executive role. Eva, who chairs the Remuneration Committee, is also a member of the Nomination Committee and the Board's People Champion, responsible for workforce engagement andensuring that colleague views and opinions are communicated to the Board.She will leave the Board with effect from31 December 2023. The Company announced that Julie Hopes will become Chair of the Remuneration Committee and the Board's nominated People Champion. Anand Aithal, Gemma Godfrey and Gareth Hoskin will become members of the Nomination Committee. These changes take effect from 31 December 2023. Following the changes above, the membership of the Company's Committees will be as follows: Audit Committee: Gareth Hoskin (Chair), Anand Aithal and Julie Hopes, Nomination Committee: Sir Peter Bazalgette (Chair), Ana. Reported Earnings • Sep 28
First half 2024 earnings released: UK£0.51 loss per share (vs UK£1.91 loss in 1H 2023) First half 2024 results: UK£0.51 loss per share (improved from UK£1.91 loss in 1H 2023). Revenue: UK£355.0m (up 13% from 1H 2023). Net loss: UK£71.0m (loss narrowed 73% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. New Risk • Aug 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Price Target Changed • Jan 24
Price target increased by 19% to UK£1.69 Up from UK£1.43, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of UK£1.68. Stock is down 39% over the past year. The company is forecast to post a net loss per share of UK£1.82 next year compared to a net loss per share of UK£0.20 last year. Annuncio • Jan 24
Saga plc to Report Fiscal Year 2023 Results on Apr 04, 2023 Saga plc announced that they will report fiscal year 2023 results on Apr 04, 2023 Annuncio • Jan 23
Saga in Discussions with Regard to a Possible Disposal of AICL Saga plc (LSE:SAGA) (Saga or the Group) noted recent media coverage about the potential sale of Acromas Insurance Company limited (AICL) and confirmed that it is in discussions with regard to a possible disposal of this business. The Board has looked at the opportunities to optimise Saga's operational and strategic position in the insurance market, in line with the evolution to a capital-light business model and the stated objective to reduce debt. It has concluded that a potential disposal of its Underwriting business is consistent with Group strategy and would crystalise value and enhance long-term returns for shareholders. AICL currently underwrites approximately 25-30% of Saga's insurance business. Discussions are ongoing and there can be no certainty that any transaction will occur. Any disposal of AICL would require regulatory and shareholder approvals. A further announcement will be made in due course. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Gemma Godfrey was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Gemma Godfrey was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Oct 15
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 losses of -UK£1.07 per share expected, vs -UK£0.84 per share profit forecast previously. Revenue forecast reaffirmed at UK£576.7m. Insurance industry in the United Kingdom expected to see average net income growth of 15% next year. Consensus price target down from UK£1.87 to UK£1.64. Share price fell 3.4% to UK£0.79 over the past week. Board Change • Oct 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Baz Bazalgette was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 27
First half 2023 earnings released: UK£1.89 loss per share (vs UK£0.022 loss in 1H 2022) First half 2023 results: UK£1.89 loss per share (further deteriorated from UK£0.022 loss in 1H 2022). Revenue: UK£259.0m (up 65% from 1H 2022). Net loss: UK£263.1m (loss widened UK£260.0m from 1H 2022). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Insurance industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Price Target Changed • Aug 19
Price target decreased to UK£2.10 Down from UK£2.27, the current price target is an average from 3 analysts. New target price is 25% above last closing price of UK£1.68. Stock is down 53% over the past year. The company is forecast to post earnings per share of UK£0.22 next year compared to a net loss per share of UK£0.20 last year. Reported Earnings • Jun 01
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: UK£0.20 loss per share (up from UK£0.67 loss in FY 2021). Revenue: UK£377.5m (up 11% from FY 2021). Net loss: UK£28.0m (loss narrowed 59% from FY 2021). Combined ratio: 40.3% (up from 26.1% in FY 2021). Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 151%. Over the next year, revenue is forecast to grow 61%, compared to a 138% growth forecast for the insurance industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Price Target Changed • Jun 01
Price target decreased to UK£3.13 Down from UK£3.43, the current price target is an average from 4 analysts. New target price is 42% above last closing price of UK£2.21. Stock is down 45% over the past year. The company is forecast to post earnings per share of UK£0.30 next year compared to a net loss per share of UK£0.20 last year. Price Target Changed • May 12
Price target decreased to UK£3.43 Down from UK£3.71, the current price target is an average from 2 analysts. New target price is 59% above last closing price of UK£2.16. Stock is down 45% over the past year. The company is forecast to post earnings per share of UK£0.37 next year compared to a net loss per share of UK£0.20 last year. Price Target Changed • Mar 23
Price target decreased to UK£3.89 Down from UK£4.78, the current price target is an average from 3 analysts. New target price is 67% above last closing price of UK£2.33. Stock is down 32% over the past year. The company is forecast to post a net loss per share of UK£0.08 next year compared to a net loss per share of UK£0.67 last year. Price Target Changed • Feb 24
Price target increased to UK£4.78 Up from UK£4.28, the current price target is an average from 4 analysts. New target price is 81% above last closing price of UK£2.65. Stock is down 29% over the past year. The company is forecast to post earnings per share of UK£0.019 next year compared to a net loss per share of UK£0.67 last year. Breakeven Date Change • Jan 31
Forecast breakeven date pushed back to 2023 The 3 analysts covering Saga previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of UK£69.4m in 2023. Average annual earnings growth of 60% is required to achieve expected profit on schedule. Price Target Changed • Jan 27
Price target decreased to UK£4.28 Down from UK£5.11, the current price target is an average from 4 analysts. New target price is 46% above last closing price of UK£2.92. Stock is up 13% over the past year. The company is forecast to post earnings per share of UK£0.059 next year compared to a net loss per share of UK£0.67 last year. Recent Insider Transactions • Nov 18
Non-Executive Chairman recently bought UK£1m worth of stock On the 16th of November, Roger De Haan bought around 341k shares on-market at roughly UK£2.93 per share. This was the largest purchase by an insider in the last 3 months. This was Roger's only on-market trade for the last 12 months. Reported Earnings • Sep 24
First half 2022 earnings released: UK£0.022 loss per share (vs UK£0.70 loss in 1H 2021) The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2022 results: Revenue: UK£156.8m (down 19% from 1H 2021). Net loss: UK£3.10m (loss narrowed 95% from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings. Price Target Changed • Jun 09
Price target increased to UK£4.80 Up from UK£4.48, the current price target is an average from 4 analysts. New target price is 14% above last closing price of UK£4.20. Stock is up 27% over the past year. Reported Earnings • May 16
Full year 2021 earnings released: UK£0.67 loss per share (vs UK£4.19 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: UK£340.0m (down 57% from FY 2020). Net loss: UK£67.8m (loss narrowed 78% from FY 2020). Combined ratio: 26.1% (down from 47.0% in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 26 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • May 08
Group CEO recently bought UK£198k worth of stock On the 5th of May, Euan Sutherland bought around 51k shares on-market at roughly UK£3.86 per share. This was the largest purchase by an insider in the last 3 months. Euan has been a buyer over the last 12 months, purchasing a net total of UK£215k worth in shares. Reported Earnings • Apr 09
Full year 2021 earnings released: UK£0.67 loss per share (vs UK£4.19 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: UK£338.3m (down 58% from FY 2020). Net loss: UK£67.8m (loss narrowed 78% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 26 percentage points per year, which is a significant difference in performance. Price Target Changed • Apr 09
Price target increased to UK£4.52 Up from UK£3.62, the current price target is an average from 3 analysts. New target price is 20% above last closing price of UK£3.77. Stock is up 50% over the past year. Price Target Changed • Mar 29
Price target increased to UK£3.62 Up from UK£3.24, the current price target is an average from 3 analysts. New target price is 9.9% above last closing price of UK£3.29. Stock is up 25% over the past year. Price Target Changed • Mar 05
Price target raised to UK£3.44 Up from UK£3.10, the current price target is an average from 4 analysts. The new target price is 14% below the current share price of UK£4.01. As of last close, the stock is up 21% over the past year. Is New 90 Day High Low • Feb 23
New 90-day high: UK£3.40 The company is up 20% from its price of UK£2.82 on 25 November 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 5.0% over the same period. Is New 90 Day High Low • Jan 21
New 90-day high: UK£3.12 The company is up 114% from its price of UK£1.46 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 25% over the same period. Is New 90 Day High Low • Nov 19
New 90-day high: UK£2.88 The company is up 33% from its price of UK£2.17 on 20 August 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Price Target Changed • Oct 13
Price target lowered to UK£4.35 Down from UK£5.16, the current price target is an average from 3 analysts. The new target price is 197% above the current share price of UK£1.47. As of last close, the stock is down 79% over the past year. Recent Insider Transactions • Oct 08
Insider recently bought UK£39m worth of stock On the 5th of October, Roger De Haan bought around 328m shares on-market at roughly UK£0.12 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£40m more in shares than they have sold in the last 12 months. 
